Background/Aims: To assess the outcomes and complications of endotamponade with Oxane HD following retinal detachment repair. Methods: Retrospective consecutive case series of inferior retinal detachment with Oxane HD endotamponade within a 3-year period. Results: Case notes for 18 eyes of 18 patients were reviewed. Four (22.2%) were total retinal detachments and 13 (72.2%) had proliferative vitreoretinopathy. The mean Oxane HD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively. The eventual anatomic success rate was 77.8%, but without any significant difference in vision. Postoperative complications occurred in 14 (77.8%), including emulsification (6 eyes; 33.3%), epiretinal membrane (5 eyes; 27.8%), and posterior capsular opacification (4 eyes; 22.2%). Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with Oxane HD developed complications. Conclusion: Although useful for inferior retinal detachments, Oxane HD was associated with a relatively high rate of emulsification when compared to other series. Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with Oxane HD, may be associated with an increased risk of intraocular complications.

1.
Azen SP, Scott IU, Flynn HW Jr, Lai MY, Topping TM, Benati L, Trask DK, Rogus LA: Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study. Ophthalmology 1998;105:1587–1597.
2.
van Meurs JC, Mertens DA, Peperkamp E, Post J: Five-year results of vitrectomy and silicone oil in patients with proliferative vitreoretinopathy. Retina 1993;13:285–289.
3.
Petersen J: The physical and surgical aspects of silicone oil in the vitreous cavity. Graefes Arch Clin Exp Ophthalmol 1987;225:452–456.
4.
Singh AK, Glaser BM, Lemor M, Michels RG: Gravity-dependent distribution of retinal pigment epithelial cells dispersed into the vitreous cavity. Retina 1986;6:77–80.
5.
Wolf S, Schön V, Meier P, Wiedemann P: Silicone oil-RMN3 mixture (‘heavy silicone oil’) as internal tamponade for complicated retinal detachment. Retina 2003;23:335–342.
6.
Theelen T, Tilanus MAD, Klevering BJ: Intraocular inflammation following endotamponade with high-density silicone oil. Graefes Arch Clin Exp Ophthalmol 2004;242:617–620.
7.
Rizzo S, Genovesi-Ebert F, Belting C, Vento A, Cresti F: A pilot study on the use of silicone oil-RMN3 as heavier-than-water endotamponade agent. Graefes Arch Clin Exp Ophthalmol 2005;243:1153–1154.
8.
Pagot-Mathis V, Benouaich X, Mathis A, Rico-Lattes I, Dumoulin A: Management of complicated retinal detachment using a heavy silicon oil as temporary tamponade (in French). J Fr Ophtalmol 2006;29:137–145.
9.
Berker N, Batman C, Ozdamar Y, Eranil S, Aslan O, Zilelioglu O: Long-term outcomes of heavy silicone oil tamponade for complicated retinal detachment. Eur J Ophthalmol 2007;17:797–803.
10.
Boscia F, Furino C, Recchimurzo N, Besozzi G, Sborgia G, Sborgia C: Oxane HD vs silicone oil and scleral buckle in retinal detachment with proliferative vitreoretinopathy and inferior retinal breaks. Graefes Arch Clin Exp Ophthalmol 2008;246:943–948.
11.
Wong D, Van Meurs JC, Stappler T, Groenewald C, Pearce IA, McGalliard JN, Manousakis E, Herbert EN: A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavier than water internal tamponade agent. Br J Ophthalmol 2005;89:662–665.
12.
Sandner D, Engelmann K: First experiences with high-density silicone oil (Densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006;244:609–619.
13.
Sandner D, Herbrig E, Engelmann K: High-density silicone oil (Densiron) as a primary intraocular tamponade: 12-month follow up. Graefes Arch Clin Exp Ophthalmol 2007;245:1097–1105.
14.
Herbrig E, Sandner D, Engelmann K: Anatomical and functional results of endotamponade with heavy silicone oil – Densiron 68 – in complicated retinal detachment. Ophthalmic Res 2007;39:198–206.
15.
Stappler T, Heimann H, Wong D, Gibran SK, Groenewald C, Pearce IA: Heavy tamponade 2. Densiron 68® in routine clinical practice: anatomical and functional outcomes of a consecutive case series. Eye 2008;22:1360–1365.
16.
Romano MR, Stappler T, Marticorena J, Groenewald C, Pearce I, Gibran SK, Wong D, Heimann H: Primary vitrectomy with Densiron-68 for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 2008;246:1541–1546.
17.
Auriol S, Pagot-Mathis V, Mahieu L, Lemoine C, Mathis A: Efficacy and safety of heavy silicone oil Densiron 68® in the treatment of complicated retinal detachment with large inferior retinectomy. Graefes Arch Clin Exp Ophthalmol 2008;246:1383–1389.
18.
Joussen AM, Kirchhof B, Schrage N, Ocklenburg C, Hilgers RD: Heavy silicone oil versus standard silicone oil as vitreous tamponade in inferior PVR (HSO Study): design issues and implications. Acta Ophthalmol Scand 2007;85:623–630.
19.
Wetterqvist C, Wong D, Williams R, Stappler T, Herbert E, Freeburn S: Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber. Br J Ophthalmol 2004;88:692–696.
20.
Majid MA, Hussin HM, Biswas S, Haynes RJ, Mayer EJ, Dick AD: Emulsification of Densiron-68 used in inferior retinal detachment surgery. Eye 2004;22:152–157.
21.
Tomlins PJ, Woodcock MGL, Spencer N, Kirkby GR: Nuclear magnetic resonance analysis of emulsified silicone oil RMN-3 (Oxane HD). Br J Ophthalmol 2007;91:1379–1381.
22.
Dresp JH, Menz D-H: Interaction of different ocular endotamponades as a risk factor for silicone oil emulsification. Retina 2005;25:902–910.
23.
Lai WW, Wong D, Li KK, Leow PL: Emulsification and inverted hypopyon formation of Oxane HD in the anterior chamber. Graefes Arch Clin Exp Ophthalmol 2008;246:1633–1635.
24.
Stappler T, Williams R, Gibran SK, Liazos E, Wong D: A guide to the removal of heavy silicone oil. Br J Ophthalmol 2008;92:844–847.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.